A Study of Gemcitabine, Cisplatin, and 5-Fluorouracil in the Treatment of Advanced Pancreatic Cancer
OBJECTIVES: I. Determine the overall survival in patients with unresectable stage III or IV
pancreatic adenocarcinoma treated with gemcitabine, cisplatin, and fluorouracil. II.
Determine the resectability rate with curative intent in patients with unresectable stage
III pancreatic adenocarcinoma treated with this regimen. III. Assess the tolerability and
toxicity of this treatment regimen in this patient population. IV. Evaluate this regimen in
terms of response rate, response duration, and overall time to disease progression in these
patients. V. Evaluate the quality of life in these patients.
OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15, followed by
cisplatin IV over 30 minutes on days 1 and 15. Patients receive fluorouracil as a continuous
infusion on days 1-15. Courses repeat every 28 days. Quality of life is assessed every 28
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Primary Purpose: Treatment
Philip A. Philip, MD, PhD, FRCP
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|